AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

November 26, 2019 GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 26, 2019--

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the Evercore ISI 2 nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 2:00 p.m. EST / 11:00 a.m. PST in Boston.

A live webcast of the fireside chat will be accessible at the Investor Calendar page under the News & Events heading of the Cortexyme investor site ( ir.cortexyme.com ). The webcast will be archived at that location for 90 days.

About Cortexyme, Inc.

Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s disease and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. The company’s lead investigational medicine, COR388, is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in patients with mild to moderate Alzheimer’s. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the final prospectus related to Cortexyme’s initial public offering filed with the Securities and Exchange Commission on May 9, 2019 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005817/en/

CONTACT: Hal Mackins

For Cortexyme, Inc.

hal@torchcomllc.com

(415) 994-0040

KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Cortexyme, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 04:05 PM/DISC: 11/26/2019 04:05 PM

http://www.businesswire.com/news/home/20191126005817/en